Hansen: 17:15: One of the things I wanted to share

Hansen: 17:15: One of the things I wanted to share related to this is that one of the first conversations I had related to this with CytoDyn leadership after running a few half days in the laboratory, they told the leadership team, this isn't just a molecule to prevent HIV, it is much more than that. Which I think I got a few people in the room to chuckle, because I think obviously, they already knew that. Basically, why I'm telling you this, I was hooked from that point on, and ever since, I've been taking a deeper dive into the mechanism of action for the various disease states including HIV, NASH and Cancer. For each of these therapeutic areas, I believe there is actually a mechanistic rationale for the use of Leronlimab. And that is actually why I am here to re-iterate what Cyrus said earlier. This is why I became a scientist. This is why I am here. I think this a phenominal molecule.

Between being exposed to Hansen's newfound enthusiasm and and Ohm's tireless affirmations on this new and lonely molecule I am becoming even more relaxed about its future. I can wait. It will take a while but I can wait. I will wait in peace.